Related Image: Treadmill Desks Combat Obesity Linked to Higher Rates of Ovarian Cancer |
(Date:7/3/2009)...ding will lead to treatments, , , FRIDA...y they,ve found a major cellular flaw that may dri...When caught early, lung cancer can often be treate...se is well advanced. Though doctors can sometimes ...prings back more virulent than ever, frequently sp...
(Date:7/3/2009)...ire-Asia/ -- Sundia MediTech, a leading,integrate...ompany in Shanghai,China announced today that Dr...ent of Chemistry Services. , Prior to joini...es, a drug,discovery and development company in S...t to Senior Director of Medicinal Chemistry of Neu...
(Date:7/3/2009)...panies and three individuals have been recognized ...tional competition designed to reward workplace he...tyXChange.org community released its 2009 Saxcies ...ww.safetyxchange.org/saxcies-video . The winners a...te their lives to keeping others safe - are detail...
(Date:7/3/2009)...Whitaker, MD, a founder of the alternative health ...ain.com, a new informational Web site devoted to a...tions. , Potomac, MD (Voc... of the alternative health movement, is now a feat...ional Web site devoted to all aspects of joint and...
Breaking Medicine News(10 mins):Health News:Cell Pathway May Be Key to Lung Cancer's Spread 2Health News:Cell Pathway May Be Key to Lung Cancer's Spread 3Health News:Sundia MediTech Appoints Dr. Chen Chen as Senior VP of Chemistry 2Health News:Excellence in Workplace Safety Recognized as 2009 Saxcies Award Winners Named 2Health News:Excellence in Workplace Safety Recognized as 2009 Saxcies Award Winners Named 3Health News:Excellence in Workplace Safety Recognized as 2009 Saxcies Award Winners Named 4Health News:Dr. Julian Whitaker Featured on Searchjointpain.com 2...of a recent study researchers say that the circadi...epeat in 24-hour cycles , can significantly impact...ercise // or receive medical treatments . During t...n 8:00 a.m. and 5:00 p.m were examined. Results f...
... the most common cancer among men, affecting about...d 220,000 new cases // of the disease are diagnose...te cancer every year. New research shows men who a...lining of their prostate ducts run a high risk of ...
...ws that people who suffer from sleep apnea run a h...sia administered // during surgery . Sleep apnea i...iodically during sleep . Statistics show the most ...obstructive sleep apnea, affects as many as 4 perc...
...a laugh signifies more than humor and ridicule, re...cal evidence // of the role of laughter during psy...e about communicating emotion than about humor. Re...s and took physiological measurements of both memb...
Other Medicine News:(Date:6/29/2009)...and, June 29 Vantia Therapeutics, ...el, small molecule drugs,targeting large, underse...rom,a Phase IIa clinical trial of its lead develo...howed that oral VA106483 was successful in produci...ct in patients, as determined by,increased osmola...
(Date:6/26/2009)...ne 26 Sanofi-aventis (... aware of data associated with a retrospective fol...these data clearly show that no definitive conclus...tionship between Lantus(R) (insulin glargine [rDNA...s, as the authors of the study point out. , , C...
(Date:6/25/2009)...Newswire-USNewswire/ -- As of mid-2009, The Michae...lready funded over $1 million in high-risk, high-r...pment through its groundbreaking Rapid Response I... of the safety and efficacy of an FDA-approved dru...erization of a tenuous link between PD and certain...
(Date:6/24/2009)...June 25 , - Recru...r the,Non-Surgical Treatment of Eye Disease With ...V (Euronext Brussels: THR), a biotechnology compan...ovative treatments for eye,disease, vascular dise...uct,microplasmin, which is in Phase III trials fo...
Breaking Medicine Technology:Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 2Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 3Sanofi-aventis Stands Behind the Safety of Lantus(R) 2Sanofi-aventis Stands Behind the Safety of Lantus(R) 3MJFF's Rapid Response Innovation Awards Hit Mid-2009 With Over $1 Million Funded in High-Risk/High-Reward Approaches to Parkinson's Disease 2MJFF's Rapid Response Innovation Awards Hit Mid-2009 With Over $1 Million Funded in High-Risk/High-Reward Approaches to Parkinson's Disease 3ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule 2ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule 3Cascade of Studies New Clinical Tests Build the Case for Genetic Testing in Pharmacy Care Says Medco Expert 37918 1Cascade of Studies New Clinical Tests Build the Case for Genetic Testing in Pharmacy Care Says Medco Expert 37918 2Cascade of Studies New Clinical Tests Build the Case for Genetic Testing in Pharmacy Care Says Medco Expert 37918 3Cascade of Studies New Clinical Tests Build the Case for Genetic Testing in Pharmacy Care Says Medco Expert 37918 4Actuaries 3A Priority on Health Reform and Retirement Security Signals Tough Choices Ahead 37916 1Actuaries 3A Priority on Health Reform and Retirement Security Signals Tough Choices Ahead 37916 2Actuaries 3A Priority on Health Reform and Retirement Security Signals Tough Choices Ahead 37916 3AIDS Action Applauds President on Appointment of Jeffrey Crowley as Director of National AIDS Policy 37914 1AIDS Action Applauds President on Appointment of Jeffrey Crowley as Director of National AIDS Policy 37914 2Alzheimers Plaques More Complex Than Thought 37912 1Alzheimers Plaques More Complex Than Thought 37912 2...2007 /PRNewswire-FirstCall/ --,Telik, Inc. announc... Phase 2 trial of the triplet combination of TELCY...paclitaxel will be,presented at the 98th annual me...rch (AACR) in Los Angeles. Preclinical studies of,...ancer cell growth,inhibition with TELCYTA in combi...
...2007 /PRNewswire-FirstCall/ --,Pharmacyclics, Inc....its novel histone deacetylase (HDAC) inhibitor and... presentations,will take place at the American Ass...eting being held April 14-18, 2007, at the Los,Ang... The presentations are as follows:, Sunday, A...
Other Medicine Technology:Telik Announces Telcyta Clinical and Preclinical Presentations at,AACR Meeting 2Telik Announces Telcyta Clinical and Preclinical Presentations at,AACR Meeting 3Pharmacyclics Announces Presentations on Its Novel and Selective,HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds 2Pharmacyclics Announces Presentations on Its Novel and Selective,HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds 3Pharmacyclics Announces Presentations on Its Novel and Selective,HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds 4...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
...rence laboratory and a worldwide leader in innovat...rs an extensive test menu of highly complex and un...ogy. Owned by the University of Utah, ARUP Laborat...n's university teaching hospitals and children's h...
Medicine Products: